Claris Biotherapeutics
Claris Biotherapeutics, Inc.
Claris Biotherapeutics, Inc. is a pioneering biotechnology company dedicated to the development of innovative therapies specifically aimed at treating corneal diseases. With a particular focus on neurotrophic keratitis (NK), a rare and debilitating condition that can lead to significant vision loss, Claris is committed to addressing critical unmet medical needs in this niche area of ocular health.
Products & Team
CSB-001
CSB-001 is a topical ocular biologic solution that harnesses the regenerative properties of recombinant human variant hepatocyte growth factor (dHGF). This product is specifically engineered to promote and expedite healing in the cornea, which is vital for restoring vision in patients suffering from corneal diseases.
CSB-001 addresses the critical need for effective therapy in patients with neurotrophic keratitis, helping to restore corneal integrity and prevent vision loss associated with this degenerative disease.
Patients experience severe discomfort, potential vision loss, and a lack of effective treatment options for neurotrophic keratitis, which can significantly impact their quality of life.